Literature DB >> 23147851

Epilepsy: perampanel-new promise for refractory epilepsy?

Wolfgang Löscher, Dieter Schmidt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23147851     DOI： 10.1038/nrneurol.2012.222

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

Review 1.  Key factors in the discovery and development of new antiepileptic drugs.

Authors:  Meir Bialer; H Steve White
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

Review 2.  Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis.

Authors:  Stefan Beyenburg; Knut Stavem; Dieter Schmidt
Journal:  Epilepsia       Date:  2009-09-10       Impact factor: 5.864

Review 3.  Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma.

Authors:  Wolfgang Löscher; Dieter Schmidt
Journal:  Epilepsia       Date:  2011-03-22       Impact factor: 5.864

Review 4.  Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?

Authors:  W Löscher; D Schmidt
Journal:  Epilepsy Res       Date:  1994-02       Impact factor: 3.045

5.  Revisiting AMPA receptors as an antiepileptic drug target.

Authors:  Michael A Rogawski
Journal:  Epilepsy Curr       Date:  2011-03       Impact factor: 7.500

6.  Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

Authors:  G L Krauss; J M Serratosa; V Villanueva; M Endziniene; Z Hong; J French; H Yang; D Squillacote; H B Edwards; J Zhu; A Laurenza
Journal:  Neurology       Date:  2012-04-18       Impact factor: 9.910

7.  Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.

Authors:  Jacqueline A French; Gregory L Krauss; Victor Biton; David Squillacote; Haichen Yang; Antonio Laurenza; Dinesh Kumar; Michael A Rogawski
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

8.  Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.

Authors:  Gregory L Krauss; Emilio Perucca; Elinor Ben-Menachem; Patrick Kwan; Jerry J Shih; David Squillacote; Haichen Yang; Michelle Gee; Jin Zhu; Antonio Laurenza
Journal:  Epilepsia       Date:  2012-08-20       Impact factor: 5.864

9.  Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.

Authors:  Jacqueline A French; Gregory L Krauss; Bernhard J Steinhoff; David Squillacote; Haichen Yang; Dinesh Kumar; Antonio Laurenza
Journal:  Epilepsia       Date:  2012-08-20       Impact factor: 5.864
  9 in total
  13 in total

1.  P-gp Protein Expression and Transport Activity in Rodent Seizure Models and Human Epilepsy.

Authors:  Anika M S Hartz; Anton Pekcec; Emma L B Soldner; Yu Zhong; Juli Schlichtiger; Bjoern Bauer
Journal:  Mol Pharm       Date:  2017-03-02       Impact factor: 4.939

2.  Ganglioside regulation of AMPA receptor trafficking.

Authors:  Jillian Prendergast; George K E Umanah; Seung-Wan Yoo; Olof Lagerlöf; Mary G Motari; Robert N Cole; Richard L Huganir; Ted M Dawson; Valina L Dawson; Ronald L Schnaar
Journal:  J Neurosci       Date:  2014-09-24       Impact factor: 6.167

Review 3.  New avenues for anti-epileptic drug discovery and development.

Authors:  Wolfgang Löscher; Henrik Klitgaard; Roy E Twyman; Dieter Schmidt
Journal:  Nat Rev Drug Discov       Date:  2013-09-20       Impact factor: 84.694

Review 4.  Glutamatergic Mechanisms Associated with Seizures and Epilepsy.

Authors:  Melissa Barker-Haliski; H Steve White
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-22       Impact factor: 6.915

Review 5.  The metabolic basis of epilepsy.

Authors:  Jong M Rho; Detlev Boison
Journal:  Nat Rev Neurol       Date:  2022-03-31       Impact factor: 44.711

Review 6.  Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies.

Authors:  H Steve White; Wolfgang Löscher
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

7.  AMPA Receptor Antagonist NBQX Decreased Seizures by Normalization of Perineuronal Nets.

Authors:  Wen Chen; Yan-Shuang Li; Jing Gao; Xiao-Ying Lin; Xiao-Hong Li
Journal:  PLoS One       Date:  2016-11-23       Impact factor: 3.240

Review 8.  Individualizing Treatment Approaches for Epileptic Patients with Glucose Transporter Type1 (GLUT-1) Deficiency.

Authors:  Armond Daci; Adnan Bozalija; Fisnik Jashari; Shaip Krasniqi
Journal:  Int J Mol Sci       Date:  2018-01-05       Impact factor: 5.923

9.  New drug classes for the treatment of partial onset epilepsy: focus on perampanel.

Authors:  Jerry J Shih; William O Tatum; Leslie A Rudzinski
Journal:  Ther Clin Risk Manag       Date:  2013-07-08       Impact factor: 2.423

Review 10.  Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.

Authors:  Wolfgang Löscher; Michel Gillard; Zara A Sands; Rafal M Kaminski; Henrik Klitgaard
Journal:  CNS Drugs       Date:  2016-11       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.